Adma Biologics Inc/ US0008991046 /
| 2024-10-18 10:00:00 PM | Chg. -0.3400 | Volume | Bid1:41:16 AM | Ask1:41:16 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 15.7800USD | -2.11% | 4.15 mill. Turnover: 48.23 mill. |
15.7800Bid Size: 100 | 15.8600Ask Size: 1,000 | -USD | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -0.13 USD | -60.61% |
| EPS Diluted: | -0.13 USD | -60.61% |
| Revenues per Share: | 1.13 USD | 63.13% |
| Book Value per Share: | 0.59 USD | -13.40% |
| Cash Flow per Share: | 0.04 USD | - |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 258.22 USD | 67.59% |
| Net Income: | -28.24 USD | -57.15% |
| Operating Cash Flow: | 8.80 USD | - |
| Cash and Cash Equivalents: | 51.35 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | - | 3.99 |
| P/BV ratio: | - | 7.63 |
| P/CF Ratio: | - | 117.22 |
| PEG: | - | - |
| Earnings Yield: | - | -2.88% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | - USD | 1.03 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 233.08 mill. | |
Profitability
| Gross Profit Margin: | 34.44% |
| EBIT Margin: | 8.38% |
| Net Profit Margin: | -10.94% |
| Return on Equity: | -20.89% |
| Return on Assets: | -8.58% |
Financial Strength
| Liquidity I / Cash Ratio: | 1.03% |
| Liquidity II / Quick Ratio: | 1.58% |
| Liquidity III / Current Ratio: | 5.16% |
| Debt / Equity Ratio: | 0.97% |
| Dynam. Debt / Equity Ratio: | 2,204.27% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
